Guardant Health (NasdaqGS:GH) introduced five new epigenomic applications for its Guardant360 Liquid test, focused on breast and lung cancers. The new tools run on the firm’s InfinityAI platform, ...
Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments